Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge

Durability of a Vesicular Stomatitis Virus-Based Marburg Virus Vaccine in Nonhuman Primates

(2014) Chad E. Mire et al.   PLoS One

Comparative Analysis of the Magnitude, Quality, Phenotype, and Protective Capacity of Simian Immunodeficiency Virus Gag-Specific CD8+ T Cells following Human-, Simian-, and Chimpanzee-Derived Recombinant Adenoviral Vector Immunization

(2013) K. M. Quinn et al.   JOURNAL OF IMMUNOLOGY

Transcriptional Profiling of the Circulating Immune Response to Lassa Virus in an Aerosol Model of Exposure

(2013) Shikha Malhotra et al.   PLoS Neglected Tropical Diseases

Clinical Assessment of a Recombinant Simian Adenovirus ChAd63: A Potent New Vaccine Vector

(2012) Geraldine A. O’Hara et al.   JOURNAL OF INFECTIOUS DISEASES

ChAd63-MVA–vectored Blood-stage Malaria Vaccines Targeting MSP1 and AMA1: Assessment of Efficacy Against Mosquito Bite Challenge in Humans

(2012) Susanne H Sheehy et al.   MOLECULAR THERAPY

Vaccine Vectors Derived from a Large Collection of Simian Adenoviruses Induce Potent Cellular Immunity Across Multiple Species

(2012) S. Colloca et al.   Science Translational Medicine

Novel Adenovirus-Based Vaccines Induce Broad and Sustained T Cell Responses to HCV in Man

(2012) E. Barnes et al.   Science Translational Medicine

SPICE: Exploration and analysis of post-cytometric complex multivariate datasets

(2011) Mario Roederer et al.   CYTOMETRY PART A

Recombinant Adenovirus Serotype 26 (Ad26) and Ad35 Vaccine Vectors Bypass Immunity to Ad5 and Protect Nonhuman Primates against Ebolavirus Challenge

(2011) T. W. Geisbert et al.   JOURNAL OF VIROLOGY

CD8+ cellular immunity mediates rAd5 vaccine protection against Ebola virus infection of nonhuman primates

(2011) Nancy J Sullivan et al.   NATURE MEDICINE

Vector Choice Determines Immunogenicity and Potency of Genetic Vaccines against Angola Marburg Virus in Nonhuman Primates

(2010) T. W. Geisbert et al.   JOURNAL OF VIROLOGY

A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults

(2010) J.E. Ledgerwood et al.   VACCINE

Heterologous Prime-Boost HIV-1 Vaccination Regimens in Pre-Clinical and Clinical Trials

(2010) Scott A. Brown et al.   Viruses-Basel

Demonstration of Cross-Protective Vaccine Immunity against an Emerging Pathogenic Ebolavirus Species

(2010) Lisa E. Hensley et al.   PLoS Pathogens

Prime-Boost Immunization with Adenoviral and Modified Vaccinia Virus Ankara Vectors Enhances the Durability and Polyfunctionality of Protective Malaria CD8+ T-Cell Responses

(2009) A. Reyes-Sandoval et al.   INFECTION AND IMMUNITY

The combination of marker gene swapping and fluorescence-activated cell sorting improves the efficiency of recombinant modified vaccinia virus Ankara vaccine production for human use

(2009) Giulia Di Lullo et al.   JOURNAL OF VIROLOGICAL METHODS

Correlates of protective immunity for Ebola vaccines: implications for regulatory approval by the animal rule

(2009) Nancy J. Sullivan et al.   NATURE REVIEWS MICROBIOLOGY